Log in to search using one of your social media accounts:

 

BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs

Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advoc... Regenerative Medicine, Neurology, Personnel BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 2 August 2017 Source:Molecular and Cellular Endocrinology Author(s): Zoltan Simandi, Attila Horvath, Ixchelt Cuaranta-Monroy, Sascha Sauer, Jean-Francois Deleuze, Laszlo Nagy Retinoid X Receptors (RXRs) are unique and enigmatic members of the nuclear receptor (NR) family with extensive and complex biological functions in cellular differentiation. On the one hand, RXRs through permissive heterodimerization with other NRs are able to integrate multiple lipid signaling pathways and are believed to play a central role to coordinate the development of the central nervous system. On the other ...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Nature Reviews Drug Discovery 16, 530 (2017). doi:10.1038/nrd.2017.144 Author: Sarah Crunkhorn Currently approved therapies for amyotrophic lateral sclerosis (ALS) — a progressive neurodegenerative disease characterized by loss of motor neurons — exhibit limited effectiveness. By screening a panel of existing drugs in induced pluripotent stem cell (iPSC)-derived motor neurons from patients with familial ALS, Imamura et
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Research Highlight Source Type: research
A common feature of neurodegenerative diseases is the formation of permanent tangles of insoluble proteins in cells. The beta-amyloid plaques found in people with Alzheimer ’s disease and the inclusion bodies in motor neurons in the brains of people with amyotrophic lateral sclerosis are two examples. Those aggregates, and others like them, can kill cells and lead to debilitating and progressive neurodegenerative diseases.A study by Douglas Black and colleagues in UCLA ’s department of microbiology, immunology and molecular genetics, reveals that not all protein aggregates in brain cells are toxic. Their paper,...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis. This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. The company said last week that Massachusetts General Hospital and California Pacific Medical Center both agreed to participate in the trial. Get the full story at our sister site, Drug Delivery Business News. The post Brainstorm adds UCal Irvine Med...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Regenerative Medicine Stem Cells Wall Street Beat BrainStorm Cell Therapeutics Inc. Source Type: news
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Contributors : Laszlo Nagy ; Zoltan SimandiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusA growing number of pieces of evidence suggest the importance of Retinoid X Receptor (RXR)-mediated pathways in neurogenesis and the dysregulation of this signaling in neurodegenerative disorders, such as Alzheimer`s or Amyotrophic Lateral Sclerosis. The data presented here identify the RAR:RXR and LXR:RXR-mediated transcriptional program in embryonic stem cells, neural progenitors and terminally differentiated neurons.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Mus musculus Source Type: research
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis. Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for treating ALS. The trial is slated to enroll approximately 200 patients at 6 sites in the US, with the primary outcome being an ALSFR-S score responder analysis. Read the whole story on our sister site, Drug Delivery Business The post Brainstorm Cell Therapeuti...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Clinical Trials Regenerative Medicine BrainStorm Cell Therapeutics Inc. Source Type: news
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 21, 2017 -- (Healthcare Sales &Marketing Network) -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology Brainstorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
In this study, for the first time, we adopted a method involving the intranasal administration of nerve growth factor combined with lateral ventricle NSC transplantation using G93A-SOD1 transgenic mice as experimental subjects to explore the treatment effect of this combined therapy in ALS. We discover that the combined therapy increase the quantity of TrkA receptors, broaden the migration of exogenous NSCs, further promote active proliferation in neurogenic regions of the brain and enhance the preservation of motor neurons in the spinal cord. Regarding physical activity, the combined therapy improved motor functions, furt...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 18, 2017 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: ALS | Biotechnology | Brain | Government | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells